Ubs Group Ag Eledon Pharmaceuticals, Inc. Transaction History

Ubs Group Ag

$527 Billion
Q4 2024

A detailed history of Ubs Group Ag transactions in Eledon Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 318,581 shares of ELDN stock, worth $1.15 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

318,581

Previous 4 7964425.0%

Holding current value

$1.15 Million

Previous $0 Infinity%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$2.45 - $5.3 $780,513 - $1.69 Million	318,577 Added 7964425.0%	318,581 $1.3 Million
Q3 2024 Nov 14, 2024	SELL	$2.41 - $3.19 $132,542 - $175,440	-54,997 Reduced 99.99%	4 $0
Q2 2024 Aug 13, 2024	BUY	$1.57 - $3.12 $86,345 - $171,590	54,997 Added 1374925.0%	55,001 $145,000
Q1 2024 May 13, 2024	SELL	$1.54 - $2.13 $850 - $1,175	-552 Reduced 99.28%	4 $0
Q4 2023 Feb 09, 2024	BUY	$1.12 - $1.86 $622 - $1,034	556 New	556 $1,000
Q2 2023 Aug 11, 2023	SELL	$1.34 - $2.85 $568 - $1,208	-424 Reduced 92.98%	32 $0
Q1 2023 May 12, 2023	SELL	$2.0 - $3.46 $7,072 - $12,234	-3,536 Reduced 88.58%	456 $1,000
Q4 2022 Feb 08, 2023	BUY	$2.17 - $2.75 $6,462 - $8,189	2,978 Added 293.69%	3,992 $9,000
Q3 2022 Nov 10, 2022	SELL	$2.45 - $3.88 $8,878 - $14,061	-3,624 Reduced 78.14%	1,014 $3,000
Q2 2022 Aug 10, 2022	BUY	$2.34 - $3.96 $10,852 - $18,366	4,638 New	4,638 $11,000
Q1 2022 May 16, 2022	SELL	$3.06 - $4.89 $11,132 - $17,789	-3,638 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$4.02 - $6.07 $14,403 - $21,748	3,583 Added 6514.55%	3,638 $16,000
Q1 2021 May 12, 2021	BUY	$9.85 - $19.22 $541 - $1,057	55 New	55 $1,000

Others Institutions Holding ELDN

# of Institutions

Shares Held

37.2M

Call Options Held

17K

Put Options Held

2.7K

View Full List

About Eledon Pharmaceuticals, Inc.

Ticker ELDN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 13,756,800
Market Cap $49.8M
Description
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that i...

More about ELDN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account